USPTO published patent application US20260091102A1 filed by Oregon Health & Science University covering a CMV-vectored vaccine platform for generating T cell immune responses against influenza. The application includes claims for methods of generating MHC-I, MHC-II, and MHC-E restricted CD8+ and CD4+ T cells, with applications for treating or preventing pathogenic infections. The technology platform may have broader applications for universal vaccine development.

This is a patent application publication, not a regulatory action. No compliance actions are required from pharmaceutical or biotechnology companies. Entities interested in licensing this technology or developing competing intellectual property should monitor the prosecution of this application through USPTO examination processes.